Annals of Oncology Q1 Unclaimed
Annals of Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 229. It is an CC BY Journal with a Single blind Peer Review review system The scope of the journal is focused on Cancer, Oncology, Systemic anticancer therapy, Molecular pathology. It has an SJR impact factor of 1,039 and it has a best quartile of Q1. It is published in English.
Type: Journal
Type of Copyright: CC BY
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
- €
Gold OA-
Green OA- €
Non OAMetrics
1,039
SJR Impact factor229
H Index1047
Total Docs (Last Year)8249
Total Docs (3 years)9316
Total Refs15748
Total Cites (3 years)7777
Citable Docs (3 years)1,85
Cites/Doc (2 years)8,9
Ref/DocAims and Scope
Best articles
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
View moreA phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
View moreA polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267
View moreA population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients
View moreAdjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials
View moreAn analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP
View moreAn individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma
View moreAnti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
View moreAre liquid biopsies a surrogate for tissue EGFR testing?
View moreAromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer
View moreAssessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcoma (STS) in a phase III randomized trial
View moreAutologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome
View moreBEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection
View moreBEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
View moreBest choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial
View moreCentralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma
View moreCirculating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer
View moreCirculating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?
View moreComing into focus: the nonovarian origins of ovarian cancer
View moreCommunication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009
View moreComparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma
View moreConko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer
View moreCrossover is not associated with faster trial accrual
View moreDealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'
View more
Comments